Allocor, Cedilanid, Ceglunat, Celanide, isolanid, lanatigen C, lanatoside C, Lanocide
| Name | Lanatoside C | ||
| PubChem CID | 656630 | ||
| Molecular Weight | 985.1g/mol | ||
| Synonyms |
Allocor, Cedilanid, Ceglunat, Celanide, isolanid, lanatigen C, lanatoside C, Lanocide |
||
| Formula | C₄₉H₇₆O₂₀ | ||
| SMILES | CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)OC(=O)C)O | ||
| InChI | 1S/C49H76O20/c1-21-43(67-38-17-32(53)44(22(2)62-38)68-39-18-33(64-24(4)51)45(23(3)63-39)69-46-42(58)41(57)40(56)34(19-50)66-46)31(52)16-37(61-21)65-27-9-11-47(5)26(14-27)7-8-29-30(47)15-35(54)48(6)28(10-12-49(29,48)59)25-13-36(55)60-20-25/h13,21-23,26-35,37-46,50,52-54,56-59H,7-12,14-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29-,30+,31+,32+,33+,34-,35-,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48+,49+/m1/s1 | ||
| InChIKey | JAYAGJDXJIDEKI-PTGWOZRBSA-N | ||
| CAS Number | 17575-22-3 | ||
| ChEMBL ID | CHEMBL506569 | ||
| Drug Bank ID | DB13467 | ||
| KEGG ID | D01972 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | ZhongLou | ||
| Use Part | Rhizome | ||
| Habitat | YunNan, GuiZhou, GuangDong, GuangXi, HuBei | ||
| Flavor | Bitter | ||
| Meridian Tropism | Liver | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Liliaceae
-->Family: Liliaceae
-->Genus: Paris
-->Species: Paris polyphylla
|
||
| Pair Name | Lanatoside C, Trastuzumab | |||
| Partner Name | Trastuzumab | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | ERBB2 | hsa2064 |
| In Vitro Model | NCI-N87 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1603 |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| In Vivo Model | NCI-N87 cells (5×10⁶/mouse/0.1 ml) were injected subcutaneously into the dorsal right flank of 6-week-old BALB/c nude mice. | |||
| Result | Our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor. | |||
